Home › Mesothelioma › Ohio
Mesothelioma clinical trials in Ohio
9 studies for Mesothelioma are looking for participants at sites in Ohio.
Cities in Ohio
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06566079SW-682 in Advanced Solid Tumors
- University Hospital of Cleveland, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06251310Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Ohio State University, Columbus
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated Jul 6, 2026 · NCT06710756Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT06051695Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- The Ohio State University Wexner Medical Center, Columbus
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Mar 9, 2026 · NCT04792463VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Taylor Cancer Research Center (site 204), Maumee
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Dec 11, 2025 · NCT03556228From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.